Skip to main content

Norway patent prosecution process.

The patent prosecution process in Norway is as follows:

1. **Filing:** 

Submit a patent application to the Norwegian Industrial Property Office (NIPO). The application can be a national application, a regional (European) application designating Norway, or an international (PCT) application entering the national phase.

2. **Formal Examination:** 

NIPO conducts a formal examination to ensure the application meets all requirements, such as correct documentation and fees.

3. **Substantive Examination:** 

If requested, NIPO conducts a substantive examination to assess the patentability criteria, including novelty, inventive step, and industrial applicability.

4. **Publication:** 

If the application meets the requirements, it is published 18 months from the filing date or priority date.

5. **Third-Party Observations:** 

Third parties can submit observations on the patentability of the application within a certain timeframe after publication.

6. **Grant or Refusal:** 

If the application is found to meet all criteria, a patent is granted. If not, the applicant may have the opportunity to respond to objections or amend the application.

7. **Validation:** 

For European patents, the granted European patent must be validated in Norway by submitting a translation of the claims into Norwegian and paying a fee.

8. **Maintenance:** 

Annual renewal fees must be paid to keep the patent in force.


It's important to note that patent prosecution procedures can change, and it's advisable to refer to the latest information from NIPO or consult legal experts for the most up-to-date guidance.


For more topics on patent prosecution ,litigation :

Click 👉 e-Pharmatimes



Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Corona virus (Covid-19)

The only way one can combat with Covid-19 is by building one’s immunity & staying healthy by proper hygiene Best medicines for immunity development could be multivitamin pills with zinc,and best foods could be #freshfruits #vegetables. #Mangoes #lemon #oranges are could be the best.

Biogen to seek approval for high-dose version of Spinal Muscular Atrophy stalwart Spinraza (Nusinersen) after trial win

Biogen, which was first to score an endorsement in Spinal Muscular Atrophy (SMA) in 2016, is endeavoring to address it with a higher portion variant of Spinraza #(Nusinersen). On Wednesday, the organization uncovered that a part of its stage 2/3 Commit concentrate on met its essential endpoint, as a higher portion of Spinraza worked on the engine capability of treatment-innocent newborn children with SMA. The review contrasted the high-portion routine with a coordinated, untreated hoax control bunch from the stage 3 Charm study, which empowered Spinraza's unique endorsement. In the Commit preliminary accomplice, 75 patients were randomized 2:1 to get the higher-portion routine or the FDA-endorsed dose of 12 mg, which incorporates four beginning medicines, trailed by support dosages like clockwork. While the high-portion form of Spinraza met the preliminary's endpoint contrasted with joke, the outcomes too "moved in favor" of the investigational routine contrasted with...